Skip directly to site content Skip directly to search


Español  Other Languages


An official website of the United States government Here's how you know
 Official icon**Official websites use .gov**
				A .gov website belongs to an official government organization in the United States. Lock icon**Secure .gov websites use HTTPS**
				A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
	CDC LogoCDC Logo
 Search

		Submit


Tuberculosis (TB)





Reported Tuberculosis in the United States, 2020						Print
																Related Pages
					Return to Main Menu
Table 10. Percentages of Tuberculosis Cases, by Initial Drug Regimen, Use of Directly Observed Therapy (DOT), and Completion of Therapy (COT): United States, 1993–2020
See Surveillance Slides #49, #50, #51, #52, and #53.
Table 10. Percentages of Tuberculosis Cases, by Initial Drug Regimen, Use of Directly Observed Therapy (DOT), and Completion of Therapy (COT): United States, 1993–2018
Year
Initial Drug Regimen1,2
Directly Observed Therapy3
Therapy <1 Year Indicated4HRZE
Multi 4+ Drug Regimen5
DOT Only
Both DOT &
Self-Administered
COT <1 Year
COT Ever1993
(40.3)
(4.9)
(21.7)
(14.4)
(63.4)
(86.0)1994
(55.7)
(5.5)
(28.1)
(20.5)
(68.6)
(86.8)1995
(62.7)
(4.8)
(37.3)
(21.5)
(74.1)
(89.2)1996
(67.3)
(4.4)
(42.5)
(22.4)
(76.8)
(90.2)1997
(71.9)
(4.3)
(47.0)
(23.8)
(78.7)
(91.0)1998
(74.3)
(4.3)
(47.7)
(26.6)
(81.2)
(92.2)1999
(76.9)
(4.7)
(49.4)
(27.6)
(81.4)
(92.2)2000
(78.5)
(4.2)
(52.5)
(25.8)
(82.2)
(92.5)2001
(79.8)
(3.9)
(53.7)
(27.5)
(82.5)
(92.7)2002
(80.3)
(4.3)
(55.4)
(27.8)
(82.9)
(92.5)2003
(81.3)
(4.7)
(56.5)
(28.5)
(83.6)
(92.7)2004
(82.4)
(4.9)
(58.9)
(27.8)
(84.2)
(92.5)2005
(83.7)
(5.0)
(57.9)
(29.6)
(84.0)
(92.5)2006
(83.3)
(6.6)
(57.5)
(30.4)
(84.8)
(93.1)2007
(83.8)
(6.5)
(56.3)
(32.9)
(85.5)
(93.8)2008
(84.2)
(7.6)
(56.4)
(33.5)
(86.0)
(93.3)2009
(84.3)
(7.8)
(59.7)
(30.2)
(88.8)
(95.6)2010
(84.5)
(8.1)
(59.3)
(31.0)
(89.6)
(96.1)20116
(85.2)
(8.1)
(62.3)
(29.1)
(89.7)
(96.5)20126
(85.4)
(9.0)
(61.8)
(29.1)
(90.2)
(96.5)20136
(84.6)
(9.5)
(63.3)
(28.8)
(89.8)
(96.4)20146
(85.3)
(9.2)
(63.8)
(29.1)
(90.3)
(96.9)20156
(85.4)
(9.2)
(65.0)
(28.5)
(90.1)
(96.4)20166
(85.0)
(10.1)
(63.9)
(30.5)
(89.3)
(95.8)20176
(83.9)
(10.4)
(61.2)
(32.9)
(90.2)
(96.3)20186
(82.9)
(11.7)
(61.3)
(33.7)
(89.1)
(95.5)20196
(82.8)
(11.7)
––
––
––
––20206
(83.3)
(10.7)
––
––
––
––Show More1Includes persons alive at diagnosis.2H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol. Excludes cases with unknown drug regimen. Data in footnote only includes the 50 U.S. states, New York City, and District of Columbia: In 2020, 64 (0.9%) received no initial drug therapy and 8 (0.1%) were started on one drug. Of 363 persons who received <4 drug regimen: top 5 regimens were 32.2% HRZ, 25.9% HRE, 6.3% HZE, 5.2% HR, and 4.7% RZE.3Includes persons alive at diagnosis with initial drug regimen of one or more drugs prescribed.4Therapy ≤1 year indicated in persons alive at diagnosis with an initial drug regimen of one or more drugs prescribed, and who did not die within one year of initiating therapy. Persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who moved out of the country within one year of initiating treatment were excluded.5Indicates at least a four drug regimen that is not HRZE only6Beginning in 2011, those who moved out of the country during treatment are excluded from the denominator of those eligible for COT.
**Note:** Data for all years updated through June 14, 2021.See Technical Notes for details and for description of COT calculation.
Double dashes (––) indicate that data are not available.Table Printing Tips
							
					
							Last Reviewed:  October 25, 2021						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisData and Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City Reports To receive email updates about this page, enter your email address: Email Address			What's this?				Submit
 Error processing SSI file


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue